Stuart More
Mohlopheni J. Marakalala
Michael Sathekge- 1Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Cape Town, South Africa
- 2Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa
- 3Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa
- 4Africa Health Research Institute, Durban, South Africa
- 5Division of Infection and Immunity, University College London, London, United Kingdom
- 6School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
- 7Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa
With Tuberculosis (TB) affecting millions of people worldwide, novel imaging modalities and tools, particularly nuclear medicine and molecular imaging, have grown with greater interest to assess the biology of the tuberculous granuloma and evolution thereof. Much early work has been performed at the pre-clinical level using gamma single photon emission computed tomography (SPECT) agents exploiting certain characteristics of Mycobacterium tuberculosis (MTb). Both antituberculous SPECT and positron emission tomography (PET) agents have been utilised to characterise MTb. Other PET tracers have been utilised to help to characterise the biology of MTb (including Gallium-68-labelled radiopharmaceuticals). Of all the tracers, 2-[18F]FDG has been studied extensively over the last two decades in many aspects of the treatment paradigm of TB: at diagnosis, staging, response assessment, restaging, and in potentially predicting the outcome of patients with latent TB infection. Its lower specificity in being able to distinguish different inflammatory cell types in the granuloma has garnered interest in reviewing more specific agents that can portend prognostic implications in the management of MTb. With the neutrophil being a cell type that portends this poorer prognosis, imaging this cell type may be able to answer more accurately questions relating to the tuberculous granuloma transmissivity and may help in characterising patients who may be at risk of developing active TB. The formyl peptide receptor 1(FPR1) expressed by neutrophils is a key marker in this process and is a potential target to characterise these areas. The pre-clinical work regarding the role of radiolabelled N-cinnamoyl –F-(D) L – F – (D) –L F (cFLFLF) (which is an antagonist for FPR1) using Technetium 99m-labelled conjugates and more recently radiolabelled with Gallium-68 and Copper 64 is discussed. It is the hope that further work with this tracer may accelerate its potential to be utilised in responding to many of the current diagnostic dilemmas and challenges in TB management, thereby making the tracer a translatable option in routine clinical care.
Introduction
Although advances in anatomical imaging of tuberculosis (TB) cannot completely characterise the natural course of this disease, nuclear medicine and molecular imaging, particularly positron emission tomography/computed tomography (PET/CT) imaging, has developed rapidly and is now able to provide information on the biology of TB at diagnosis and in assessing treatment response.
From a historical perspective, Gallium-67-citrate ([67Ga]Ga-citrate) was one of the first radioisotope workhorses used in the management of TB and had been employed in the clinical practise to give an indication of disease activity, response assessment, and disease extent (1, 2) including the ability to differentiate infection from Mycobacterium tuberculosis (MTb) from non-MTb lesions (3). Work had also been performed in patients coinfected with human immunodeficiency virus (HIV) (4–6).
Thallium-201 chloride[201Tl] has been used in some works to distinguish malignant lesions from tuberculous ones (7–9), with further work demonstrating its role in characterising pulmonary and extrapulmonary TB (10–12). Similar early work was performed with Technetium 99m sestamibi (MIBI) ([99mTc]Tc-MIBI) and [99mTc]Tc-tetrofosmin in the management of TB (13–17).
2-deoxy-2-[18F]fluoro-D-glucose (2-[18F]FDG) has been the most widely studied PET radiopharmaceutical in TB, with a growing interest in Gallium-68-based radiopharmaceuticals. As we anticipate a more specific solution to answer the biology of the granuloma, the neutrophil has shown to play a key role in the pathogenesis of TB, with their presence of neutrophils predicting increased disease severity.
Figures 1, 2 show a schematic review of the targets of the various radiopharmaceuticals discussed in this review based on their mechanism of action (please also refer to Table 1).
Figure 1. Schematic representation of a host cell and the radiopharmaceuticals listed according to their mechanisms of action.
Figure 2. Schematic representation of Mycobacterium tuberculosis bacillus and the radiopharmaceuticals listed according to their mechanisms of action.
Table 1. An overview of the tracers used in imaging and characterising TB (apart from Gallium-68-labelled radiopharmaceuticals).
It is the hope of this review to look at the current molecular imaging modalities available in mapping out TB and review the potential role a neutrophil-specific tracer may have in the management of TB.
Methodology
A comprehensive literature search was performed in the PubMed, EbscoHost, Web of Science Scopus, and Cochrane databases to identify articles published up until June 2021 regarding the role of nuclear medicine and molecular imaging in imaging TB, particularly neutrophils and utility of a neutrophil-specific tracer and the potential role of imaging the TB granuloma. Different combinations of search terms (and their various permutations) were used including “neutrophil,” “leucocyte,” “nuclear medicine,” “PET/CT,” “SPECT/CT,” “SPECT,” “99mTc,” “HMPAO,” “Indium111-oxine,” “F18,” “FDG,” “Copper64,” “Gallium-68,” “tuberculosis,” “granuloma,” “FPR1,” and “cFLFLF” “radiolabelled antituberculous treatment.” The references of the resultant articles were also used to identify additional manuscripts. A total of 182 key articles were identified that discussed the spectrum of nuclear medicine and molecular imaging in TB, with the role of neutrophil-specific imaging in this context. These articles form the basis of this manuscript.
TB IN 2021
Although there have been many major advances in the field of medicine, TB continues to be one of the world's most devastating diseases, resulting in marked morbidity and mortality. According to the WHO Global Report 2020, 10 million (range 9–11 million) people worldwide contracted TB in 2019, with ~1.2 million (range 1.1–1.3) dying of the disease, which included about 2,51,000 patients who also had HIV co-infection (63). More recently, the current prevalence rates of TB in South Africa are estimated at 852 per 1,00,000 in a recent survey conducted by the South African Medical Research Council (64). Diagnostic imaging of TB includes both plain chest radiographs (CXR) and computed tomography (CT) in more resourced areas. Anatomical imaging (including MRI) is limited in detailing the early stages of TB infection, and changes may only be evident once there has been significant tissue damage or alteration thereof, particularly in the later stage of most diseases. They also are limited in distinguishing sterile inflammation from infection or differentiating between different aetiologies of disease (65). PET/CT imaging has begun to make some traction in being able to answer some of these questions, it is, however, still not fully validated yet for routine clinical use.
Culture remains the reference standard for the diagnosis of TB; however, the culture takes between 2 and 8 weeks to grow sensitive bacteria and is dependent on the burden of mycobacteria present in the sample (66). The Xpert MTB/RIF assay in recent times has added to the tools available to diagnose TB, the test rapidly detects DNA of MTb nucleic acid present in sputum and simultaneously assesses genetic mutations predicting rifampicin resistance. The specificity is comparable to that of culture at 98% (67). The Xpert MTB/RIF ultra, which utilises the same GeneExpert platform as Xpert MTB/RIF, was recommended by the WHO in 2017 owing to its improved sensitivity (63). The major limitation of these assays is the inability to monitor disease when compared to culture (44). Other methods for the detection of TB have been developed which are still being validated for routine clinical use (68).
Hence, other non-invasive methods have been developed to assist in the diagnosis of MTb.
Nuclear medicine and molecular imaging, with its ability to trace pathophysiological processes using radiopharmaceuticals, are seen as a viable option and adjunct in the holistic management of TB.
Role in Imaging Tb Using Gamma Spect Agents
Molecular imaging has been utilised within the pre-clinical framework and translated into the clinical setting with several imaging probes having been developed to assist in the diagnosis of infection and inflammation. Single photon emission computed tomography (SPECT) molecular probes were developed to assist in the diagnosis and management of TB, aiming to improve the specificity of the detection of MTb infection.
One of the first studies evaluated Technetium 99m sestamibi (MIBI) ([99mTc]Tc-MIBI) and ([99mTc]Tc-tetrofosmin) in TB, demonstrating high uptake of the tracers owing to increased mitochondrial content of the epithelioid cells in the granulomatous lesions (22). Increased uptake of [99mTc]Tc-MIBI was also seen in MTb cells when compared to myocytes or fibroblast cultures (with peak activity shown at 15 min), paving the way to understand the mechanism of uptake in MTb cells (23).
The nucleoside 1-(2′-deoxy-2′-fluoro-b-D-arabinofuranosyl)-5- iodouracil (FIAU) (also known as fialuridine) labelled with iodine-125 has also been utilised as a tracer to assist in invasive detection and localisation of MTb (69). FIAU forms part of the nuclear acids used by microorganisms and is a substrate for bacterial thymidine kinase (TK). Phosphorylation by TK allows for trapping within microorganisms. When MTb was modified to express bacterial TK, [125I]I-FIAU was shown useful to measure mycobacterial load in infected mice (24).
Work related to the role of activated macrophages which express translocator protein on the mitochondrial membrane for lipid transport has been explored, predominantly within the neuropsychiatric spectrum (70, 71). The translocator protein (TSPO) is an 18-kDa trans-mitochondrial membrane channel used for the transport of cholesterol and other endogenous ligands. TSPO is also expressed highest in steroidogenic tissues, heart, lungs, and immune cells such as macrophages. Radiolabelled N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide (DPA713) has been used as a target to map out inflammation associated with pulmonary TB and has been shown to preferentially accumulate in macrophages and phagocytic cells (25). When [125I]I-DPA713 was compared to 2-[18F]FDG in a mouse model, uptake of [125I]I-DPA713 was found to be more discrete when compared to 2-[18F]FDG which showed more diffuse uptake in tuberculous lesions (25, 26).
In antibody-mediated work, [131I]I-anti-BCG antibody was used as a potential target for TB owing to the similarity between MTb and Mycobacterium bovis. In a pre-clinical rabbit model, it was shown to localise to tuberculous lesions but was also seen in other organs such as the heart, liver, spleen, and kidneys (27). No further significant work has been performed with this agent, besides Lee et al. who used the antibody fragment F(ab)′ against BCG with radiolabelled with 131I. The tracer accumulated in tuberculous lesions in rats while being cleared from syphilitic lesions in the same animal model (28).
[99mTc]Tc-tilmanocept, which is a molecular marker for the mannose receptor CD206, has been utilised in lymphoscintigraphy in oncology (72, 73) and also limited phase 1 studies in mapping atherosclerotic inflammation (74) and rheumatoid arthritis (75, 76). Enhanced expression of CD206 in macrophages, particularly in lung and pleural tissue with caseating granuloma, has portended a poorer prognosis in patients with these lesions (77). Therefore, [99mTc]Tc-tilmanocept may be a future marker for mapping the physiology of the granuloma which is currently underway with a PET-labelled tracer, [68Ga]Ga-tilmanocept (78).
Radiolabelled Antituberculous Spect Agents
The rationale of using radiolabelled antituberculous drugs has long been developed and not necessarily translated into clinical care but has given context into understanding the bioavailability and pharmacokinetics of the drugs used in the treatment regimen of TB.
Radiolabelled isoniazid as 2-[123I]-iodoisonicotinate was initially pioneered with the potential to assist in differentiating intracranial masses (tuberculoma vs. glioma), and CNS TB in immunosuppressed subjects (29). Owing to the low labelling efficiency (LE), better complexes were developed by Singh et al., showing more than 95% LE and persistent uptake in tubercular lesions in rabbits, with transient uptake seen in non-tuberculous lesions (30, 31). This level of LE was also seen by Roohi et al., whose results were concordant with Singh et al. (79) Samuel et al. (80) performed another pre-clinical study but did not show any clinically significant uptake by MTb in the in vitro cell-binding studies. Similar work has been demonstrated using [99mTc]Tc – IFC, an isoniazid derivative (33). [99mTc]Tc-alginate INH microspheres were utilised in rabbits, demonstrating 96% LE and showing moderate lung uptake in TB lesions (32). Clinical translation of radiolabelled isoniazid was seen in six patients who had confirmed extrapulmonary TB, demonstrating moderate uptake in these lesions (81). No further work has been seen with gamma agent translation of radiolabelled isoniazid.
Radiosynthesis and biodistribution of [99mTc]Tc-rifampicin has only been seen in the pre-clinical evaluation of MRSA in artificially infected rats and rabbits. Gamma radiolabelled agents have not been translated to mapping TB infection (82). It is important to note that no further investment has been made into the translation of Technetium 99m-based radiopharmaceutical for TB imaging using rifampicin.
Targets using Technetium 99m-labelled ethionamide ([99mTc]Tc-N-IFC) were also explored in the pre-clinical context and as with [99mTc]Tc-rifampicin and have not progressed beyond the pre-clinical stage (34).
[99mTc]Tc-Ethambutol was initially developed for studying renal excretion and brain imaging owing to the similar structure to its derivatives (35). With ethambutol's key mechanism of action being the inhibition of cell wall synthesis of MTb, the utility of radiolabelled ethambutol has been investigated to highlight the clinical efficacy of therapy in the management of MTb. Recent work has demonstrated a sensitivity and specificity of 94.9 and 83.3%, respectively, for detecting TB at any sites (PTB and EPTB) with microbial culture used as the gold standard (37). Work related to [99mTc]Tc-ethambutol in spinal TB has also been explored (83). Current limitations of this agent include uptake in normal parenchyma (which will preclude visualisation of areas with uptake above background activity), liver excretion (which hampers the assessment of potential abdominal TB), and overall poorer target to background ratio as a result of the former pitfalls described (36).
Other radiolabelled TB drugs such as [99mTc]Tc-ciprofloxacin have been utilised in clinical practice to differentiate between active and inactive TB (84) and assess response to therapy (85) with the limited widespread clinical application (38). More specific probes have subsequently been developed which have limited widespread clinical application of [99mTc]Tc-ciprofloxacin.
Despite radiolabelled leukocytes and antibodies being the standard in infection and inflammation imaging in a variety of conditions (86–88), most of the radiolabelled cells (predominantly neutrophils) may be less sensitive as a gamma agent in imaging TB (89). There have been very few studies demonstrating the use of radiolabelled white cells in imaging TB, with limited scope in translation into the routine clinical space (90–93). Other non-specific agents have been utilised over the last 20 years to map out the pathophysiology of MTb and including previously mentioned [67Ga]Ga-citrate (18–21), [99mTc]Tc-MIBI, [99mTc]Tc-tetrofosmin, [201Tl]Tl-chloride and less utilised tracers such as [123I]I-IMP, [99mTc]Tc-DMSA, [99mTc]Tc-citrate, [99mTc]Tc-glucoheptonate, [111In]In-octreotide, [99mTc]Tc-MDP, and [99mTc]Tc-ECD (94). With the advent of PET probes, these have very limited utility in the management of TB.
Of the list above, [67Ga]Ga-citrate has been the agent with the most breadth of clinical data (3) and can be used in a setting where PET availability is scarce. In addition, the complexity of timing required to complete these studies and the higher radiation burden associated with [67Ga]Ga-citrate has made its use less routine.
Role of Pet Probes in Imaging TB
PET/CT combines the anatomical information obtained from the CT with the functional aspect using a specific radioisotope combined with a pharmaceutical that traces a specific aspect of physiology or pathophysiology.
2-deoxy-2-[18F]fluoro-D-glucose (2-[18F]FDG) has revolutionised care in oncology owing to its mechanism of action. In the Warburg effect, tumours will consume more glucose than other tissues which is primarily what is exploited in PET/CT imaging using 2-[18F]FDG as a tracer (95). Within cancer cells, uptake of 2-[18F]FDG is mediated by glucose transporters (GLUT). GLUT1 is the most common of these transporters, with tumours also expressing GLUT3. Once 2-[18F]FDG is in the cell, 2-[18F]FDG is phosphorylated by hexokinase (HK) giving 2-[18F]FDG-6-phosphate which, unlike glucose, cannot be further metabolised owing to its lacking the hydroxyl group (96). Most tumours, in addition, also express HK2, one of the four isoforms of HK. 2-[18F]FDG-6-phosphate can only leave the cell by dephosphorylation, which is catalysed by glucose-6-phosphatase.
Inflammatory cells can also express increased levels of GLUT1 and 3 (particularly macrophages, neutrophils, and other inflammatory cells) and increased HK activity (96). Some bacteria have also been found to contribute to 2-[18F]FDG uptake by actively taking up the radiotracer (97).
The differential in uptake between inflammatory and normal cells has been shown in tumour tissue by autoradiographic techniques (39). It is this interaction between inflamed tissue when compared to normal cells that is the basis for 2-[18F]FDG uptake in TB.
2-[18F]FDG PET/CT in the imaging of TB has been widely investigated. 2-[18F]FDG has been used to assess TB lesion activity globally, characterise uptake in the lung and mediastinal lymph nodes (45–47), assist in patients by predicting those who may develop TB in latent TB infection (LTBI) (98) identification of subclinical TB, differentiating TB from malignant lesions, differentiating TB from non-tuberculous mycobacterial infections (99, 100), response assessment to TB treatment and also characterise extrapulmonary TB (44, 48, 49, 98).
Non-Fdg Pet Tracers
Other PET tracers have been used in the imaging of TB to trace different aspects of the pathophysiology of MTb. Choline-based derivatives can image the utilisation of choline in the wall of MTb (which is composed of many complex lipids) (50, 51). 3′-deoxy-3′-([18F]fluoro)-fluorothymidine [[18F]fluoro- L-thymidine (FLT)] can be used as a surrogate for cell proliferation as thymidine incorporates into the DNA of the bacterium. [18F]FLT has been evaluated in distinguishing malignant from benign lesions in conjunction with 2-[18F]FDG (52, 101). [18F]F-sodium fluoride (Na[18F]F) has only been used in the murine model but has the potential for use in detecting chronic TB from acute infection (102). [124I]I-DPA713 was utilised in a paediatric rabbit model of tuberculous meningitis to show its ability to detect MTb where it was localised to the activated microglia/macrophages around the TB lesion. These findings were confirmed with immunohistochemical techniques (53).
2-deoxy-2-[18F]fluoro-d-sorbitol (2-[18F]FDS) is a tracer that was initially designed for tumour imaging but found to have limited use owing to the low accumulation of the tracer in vitro (103). 2-[18F] FDS has been shown to have pathogen-specific uptake by bacteria and has the ability to distinguish bacterial infection from sterile inflammation (104). The application of 2-[18F]FDS in TB may be limited owing to the lack of gene expression of sorbitol subunits in the mycobacteria (105). Experiments have been performed with mycobacteria at the pre-clinical level with no uptake of 2-[18F]FDS seen in MTb (57).
Despite the efforts of aiming to characterise TB with these non-FDG PET tracers, much more work is required before they can be translated to clinical care.
Radiolabelled Antituberculosis Pet Agents
Both pyrazinamide and isoniazid have been radiolabelled with PET agents but have yet to have further clinical translation because of their pharmacokinetic properties (54–56).
Radiolabelled rifampicin with PET has shown some promise, with pre-clinical work in mice determining the pharmacokinetics of Carbon 11-rifampicin ([11C]-rifampicin) in MTb-infected mice. This work showed lower concentrations of tracer in infected necrotic lung specimens when compared to healthy tissue (58). More recently, [11C]-rifampicin was used in a first in human trial to map out the antimicrobial concentration time profiles of rifampicin in subjects who were proven with rifampicin-sensitive pulmonary TB. [11C]-rifampicin had spatially compartmentalised rifampicin exposure in pathological distant TB lesions, with uptake lowest in the wall of tuberculous lesions and cavities, which may have implications for the development of future host-directed therapies (59). PET tracers such as [18F]F-linezolid (60) and Bromine-76 bedaqualine ([76Br]Br-bedaqualine) (61) have also been utilised in the pre-clinical setting in murine models with some promise in potential clinical translation.
Gallium-68 Pet Imaging - Not So New Kid on the Block
The advent of the radioisotope Gallium-68 (68Ga) has revolutionised molecular imaging owing to the favourable physical properties of the radioisotope. Gallium-68 is produced from a Germanium-68/Gallium-68 generator (with the parent isotope having a half-life of 270.8 days) and allows for its use for up to 1 year (106). The half-life of 68Ga (68 min) mirrors the pharmacokinetics of many well-known peptides and molecules owing to their fast clearance from the blood its biggest impact thus far has been in the imaging of neuroendocrine tumours (107) (when radiolabelled to a somatostatin analogue) and recently with the ligand prostate-specific membrane antigen (PSMA) (108).
The growing interest in infection imaging with 68Ga has grown considerable over the last decade (109). A growing number of radiopharmaceuticals chelated to 68Ga have been studied within both clinical and pre-clinical settings (refer to Table 2).
Table 2. Infection imaging with Gallium-68-labelled compounds.
Pre-Clinical Work With Gallium-68
Agents targeting the MTb cell wall were developed by Ebenhan et al. to detect inflammation. The depsipeptide NH2-l-proline-l-Leucine-l Proline-l-Valine-L-leucine-l-Thronine-l-Isoleucine-OHH(TBIA101) when chelated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) showed uptake of [68Ga]Ga-DOTA-TBA101 in MTb-infected rabbits. It was, however, not able to distinguish sterile inflammation from infection (111, 112).
Hypoxia imaging has also played a role in mapping out the pathophysiology of TB granulomas (124). Hypoxia plays a fundamental role in switching metabolism in MTb to an inactive state which promotes non-replicating persistent bacteria (125). Imaging the microtumour environment in cancer using radiolabelled hypoxia agents has been established and as such can potentially play a role in managing MTb (126). Fluorine-18 fluoromisonidazole ([18F]FMISO) demonstrated severe hypoxia in tuberculous lesions in five patients as a primer for clinical translation (62). This is awaiting further clinical translation with a novel Gallium-68-based hypoxia agent to characterise the granuloma environment in TB (125).
The natural antimicrobial agent ubiquicidin (UBI) has been studied over the last decade as an attractive infection imaging agent both with SPECT and with PET agents (127). UBI is a 51 amino acid derivative that has an affinity for targeting bacterial cell wall synthesis. Preliminary results in the pre-clinical setting have shown bacteria-specific binding in rabbits infected with Staphylococcus aureus when [68Ga]Ga-NOTA-UBI30-41 was utilised (110). 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)- labelled peptides have also been utilised in infection and inflammation imaging (128). [68Ga]Ga-NOTA-UBI has been utilised in the clinical setting demonstrating moderate uptake in a patient with active pulmonary TB (109). However, this should be reviewed to further validate this agent (109, 129).
Clinical Translation Of Gallium-68-Labelled Agents
Gallium-68 citrate ([68Ga]Ga-citrate) has been used as a utility for assessing lesion activity, especially in staging a patient with proven TB. It localises to inflammatory foci by non-specific and specific transferrin dependent and independent mechanisms which are like [67Ga]Ga-citrate (129). Preliminary work in a pilot study performed in Pretoria, South Africa reviewed [68Ga]Ga-citrate for diagnosis of indeterminate lung lesions (113). Of the patients who were proven to have TB, the work found that tuberculous lesions visible on CT had significant uptake with other lesions (e.g., lung cancer and other benign lesions) having less significant uptake. A follow-up study (5 years later) focusing on patients with proven TB demonstrated uptake in both pulmonary and extrapulmonary TB lesions (117). When compared directly with 2-[18F]FDG PET/CT in patients with TB, 2-[18F]FDG detected more lesions than [68Ga]Ga-citrate. However, [68Ga]Ga-citrate had better detection in intracranial TB and is a better agent to use in this context owing to the biodistribution of [68Ga]Ga-citrate (118). Intracranial TB has also had limited utility using Gallium-68-NOTA-arginine-glycine-aspartic acid (RGD) ([68Ga]Ga-NOTA- RGD) as a potential agent (109).
[68Ga]Ga-alfatide II is a marker of angiogenesis. In TB lesions, it has been shown that there is a decrease in the microvessel density from the edge of the granuloma to the central avascular region. Within malignant lesions, the expression of angiogenesis will be much higher. It is this difference that was exploited by Kang et al. to compare to the difference of 2-[18F]FDG and [68Ga]Ga-alfatide II in differentiating TB and non-small cell lung cancer (NSCLC) (114). The uptake of [68Ga]Ga-alfatide II in NSCLC lesions was significantly higher than in TB lesions, hence [68Ga]Ga-alfatide II was able to distinguish NSCLC from TB when compared to 2-[18F]FDG using angiogenesis as a model.
Gallium-68 PSMA ([68Ga]Ga-PSMA) has had much traction recently in its utility in primary staging of high-grade prostate cancer, detection of biochemical recurrence, planning patients for radioligand therapy (130, 131). PSMA is a type II transmembrane glycoprotein that is overexpressed in prostate cancer (132). [68Ga]Ga-PSMA has shown many other pathologies which may display uptake of PSMA, particularly in some tuberculous lesions (116).
Pyka et al. in their series of patients showed uptake in two tuberculous lesions, albeit not to be to the same intensity as the prostatic lesions (115). Several case reports have seen PSMA uptake in tuberculous extrapulmonary lesions such as the spine (119), skull (116), and brain (120). No work has been shown in its utility in the management of TB but should be considered as an important pitfall, particularly in TB endemic areas.
Gallium-68 labelled somatostatin receptor imaging (labelled as [68Ga]Ga-DOTANOC), [which is a target for somatostatin type 2 receptors and is overexpressed by activated macrophages (133)] has been studied in conjunction with 2-[18F]FDG to characterise lesions in TB. The authors concluded that [68Ga]Ga-DOTANOC can detect pulmonary TB lesions, but that 2-[18F]FDG is still more sensitive for both active and subclinical lesions (121).
Fibroblast-activated protein (FAP) is highly expressed within the stroma of a variety of tumours. Gallium-68 labelled FAP inhibitor (FAPI) has demonstrated its convincing utility in several oncologic applications (134–136), with advantages being no major patient preparation and improved better target to background ratio in some cases. There are a few cases using [68Ga]Ga-FAPI in incidental detection of TB in lymph nodes (122) and intracerebral TB (123) and may bear some promise as the tracer develops further into evaluating other non-oncologic applications.
The Fundamental Problem of The Tuberculous Granuloma
One of the key problems in the pathogenesis of TB is the development of the granuloma, which is the pathological hallmark of this disease (137, 138). Heterogenous forms exist with a spectrum of host outcomes (137, 139, 140). Transmissive granulomas harbour an abundance of neutrophils which will either protect the host by driving cell priming and granuloma formation or promote disease severity (141). Neutrophils recognise MTb by releasing lysosomal enzymes, human neutrophil peptides, and a host of other reactive oxygen species which aim to lyse the mycobacterium. A second mechanism exists where neutrophils release neutrophil extracellular traps which aim to trap the microbe and thereby present its further action on the host (142, 143).
It has been shown that neutrophilia portends a poorer prognosis and independently predicts death in patients with TB (144). The ability to image the neutrophil and its role in TB pathogenesis will assist in identifying factors promoting immunopathology, which may be targeted for the development of specific host-directed therapies that will add to the current armamentarium of diagnostic and therapeutic options available for TB. Neutrophils may be found in patients with LTBI and may have a role in identifying those patients that may be at risk of developing the active disease (145). With 2-[18F]FDG being a glucose analogue, its mechanism of uptake [which is driven by glycolytic metabolism for generation of adenosine triphosphate (ATP)] does not allow for differentiation between different immune cell populations (40, 98, 146). This is despite multiple studies reviewing the utility of quantitative measures to be able to predict response to therapy in patients with pulmonary and extrapulmonary TB (147–151) (including dual-time-point imaging) (44).
Introducing the Formyl Peptide Receptor
Leucocytes will accumulate at sites of inflammation by responding to pathogen and host-derived factors known as chemo attractants. The formyl peptide receptor (FPR), a G protein-coupled receptor, has the ability to recognise the N formyl methionine motif in synthetic neutrophil chemotactic peptides (152). It is a classic G protein-coupled receptor with seven transmembrane-spanning regions with an N terminus (extracellular) and C terminus (intracellular), and three loops exposed on the cell surface for ligand interaction (153).
FPR1, in particular, is expressed by neutrophils, which play a fundamental role in chemotaxis, killing microorganisms through phagocytosis, and the generation of reactive oxygen species (154, 155). These peptides were first seen to be an attractant for neutrophils in early pre-clinical work (156–158).
As a result of early work performed using the Escherichia coli-derived synthetic ligand formyl-methyl-leucine-phenylalanine (fMLF), much is now known on the properties of FPR1. Once FPR1 is activated, fMLF is internalised within 30 seconds and then leads to a cascade of events which include transcription regulation, superoxide production, degranulation, cytokine expression, and changes in cell surface marker expression (159).
A Brief History of The Fpr1 Molecular Probe
In the early 1990s, work was performed with 99mTc-labelled chemotactic peptide receptor antagonist [N-fMLF-lysine(N-For-MLK)] with high biological retention and receptor-binding activity in sites of infection in rats and rabbits (160–162). The tracer also showed a high target to background ratio seen when compared to radiolabelled leucocytes (163) or human polyclonal immunoglobulin G (164). The problem with this agent was the poor image quality owing to its high lipophilicity which resulted in higher liver uptake (161). This peptide [N-cinnamoyl –F-(D) L – F – (D) –L F (cFLFLF), an antagonist for FPR1], has been explored with a new agent polyethylene glycol (PEG) to decrease the lipophilicity and mitigate liver uptake and aimed to radiolabel with Copper 64(64Cu). Copper 64 has a half-life of 12.7 h and a unique decay profile which makes it attractive for radiolabelling with various peptides and molecules for PET/CT imaging and potential radionuclide therapy (with emission of Auger electrons and β-particles) (165, 166). In the mouse model, this was able to detect lung inflammation (167). This was confirmed two years later where [64Cu]Cu- (PEG)-cFLFLFK has been shown to bind to FPR1, accumulating at sites of inflammation in vivo, with LE of more than 95%. Work with this tracer in mice infected with Klebsiella confirmed that the cellular infiltrates in the lungs was exclusively neutrophils at the time of imaging (confirmed with immunohistochemistry) (168). This has also been confirmed with another radiolabelled tracer, [68Ga]Ga-nanotracer-cFLFLF, in the murine model with clinically proven relevant neutrophil recruitment to sites of infection and LE >97% (169).
Pre-Clinical Technetium 99M-Based Applications
99mTc-labelled-cFLFLF was considered owing to the ready availability of 99mTc from its parent isotope, molybdenum-99. [99mTc]Tc-PEG12-TKPPR-cFLFLF had a high affinity for neutrophils and was stable in serum with sufficient hydrolipophilicity (170). The probe showed feasibility for in vivo imaging of acute neutrophilic inflammation in the murine model. Stasiuk et al. also demonstrated the feasibility of [99mTc]Tc-cFLFLFK-NH2 in the murine model to show inflammation non-invasively (171–173).
Chen et al. reviewed using [99mTc]Tc-cFLFLF in rats with acute osteomyelitis (AO). This group used both methylene diphosphonate (MDP) (a bone-seeking agent with clinical utility in osteomyelitis) (86) and 2-[18F]FDG (87, 174) to ascertain early diagnosis and therapeutic monitoring of AO. The work aimed to investigate [99mTc]Tc-cFLFLF in the rat model of AO and compare it with conventional imaging with [99mTc]Tc-MDP bone scan and 2-[18F]FDG. The group had 40 rats which were divided into eight groups (A–H) of five each. Three of these groups were designated as sham controls (D, E, and F) and the remainder were the AO models. Groups A and D had [99mTc]Tc-cFLFLF scintigraphy, Groups B and E had [99mTc]Tc-MDP, and Groups C and F had 2-[18F]FDG. [99mTc]Tc-cFLFLF was superior to [99mTc]Tc-MDP and 2-[18F]FDG in the detection of acute AO with a high affinity for neutrophil binding with FPR1. In addition, the probe was able to monitor the effects of therapy for AO, highlighting the ability of [99mTc]Tc-cFLFLF in diagnosis and monitoring of therapeutic interventions (175).
Another group aimed to exploit the pathophysiology of acute intervertebral disk herniation by tracking leukocyte filtration using FPR1-mediated molecular imaging. Using SPECT and near-infrared fluorescence imaging (NIRF), the probe [99mTc]Tc-HYNIC-PEG-cFLFLF was injected into sham- and disc-injured mice. Neutrophils were detected from days 1 to 3 with the preferential accumulation of [99mTc]Tc-HYNIC-PEG-cFLFLF in herniation sites, hence demonstrating directly and non-invasively the utility of FPR1-targeted molecular imaging in tracking inflammatory processes (176).
FPR1-mediated imaging has a role in the non-invasive diagnosis of lung ischaemic reperfusion injury post-lung transplantation which can lead to primary graft dysfunction (PGD) as the main morbidity (177). Lung inflammation was seen on SPECT imaging in mice with [99mTc]Tc-cFLFLF at 2, 12, and 24 h post-reperfusion. A porcine model was used to confirm its translational aspect. This may have implications in the early diagnosis of PGD which impacts therapeutic interventions and outcomes of patients (178, 179).
In another study mapping the pathogenesis of abdominal aortic aneurysms (AAA), [99mTc]Tc-cFLFLF was used to track the role of neutrophil infiltration and activation in the evolution of AAA. In the murine model, an elastase treatment model of AAA was developed. [99mTc]Tc-cFLFLF was observed to accumulate in aortic tissue treated with elastase when compared to the controls. A marked increase in neutrophil accumulation was observed in aortic tissue, confirming the role of non-invasive molecular imaging to help map out pathophysiology using [99mTc]Tc-cFLFLF (180).
Translation Into Work With TB
More recent work with TB granulomas using human neutrophils and a mouse model was performed to evaluate the in vivo cellular specificity of cFLFLFK-PEG12-Cyanine 3(Cy3) within a human in vitro granuloma model and a mouse model of lung granulomatous inflammation (181). The human neutrophils were taken from patients who had LTBI. The probe used in the work was found to preferentially bind to neutrophils than to monocytes or lymphocytes in human cells. In the mouse model, cFLFLFK was found to be accumulating more within the granulomatous inflammatory responses in the lung, preferentially localised to the neutrophils and cells of the monocyte or macrophage lineage (181). This has set the ground for aiming to understand granuloma biology and the role of cells expressing FPR1 in contributing to TB pathogenesis. In the macaque model, cFLFLF peptide binds specifically to neutrophils in inflammatory cells in the mouse model, to neutrophils in macaque blood, and neutrophils in the granulomas from the necropsy. It bound poorly to macrophages and lymphocytes (41). This was further translated recently in comparison with 2-[18F]F-FDG where [64Cu]Cu-cFLFLF was retained in lung granulomas in MTb-infected cynomolgus macaques. There was a positive correlation with neutrophils and macrophages (and to a lesser extent T and B cells) when the granulomas were further analysed (42).
Future Perspectives
The neutrophil is known to be part of both host protection and inflammation processes causing damage in TB. The abundance of neutrophils within a granuloma is associated with a poorer prognosis and mortality in TB. In patients with TB granulomas, the presence may result in progression to active TB from an LTBI. This is particularly relevant in lesions where there is a high mycobacterial load or some form of immune dysfunction. These are inherently dependent on the host immunity, stage of disease, and virulence of the mycobacterium itself (144, 182).
Molecular imaging, particularly FPR1-mediated molecular imaging, has great potential in being able to assist in the management and therapy of a wide variety of pathological diseases and processes.
The utilisation of these novel probes will be able to characterise transmissive granulomas from those that are protective (refer to Figure 3). This could enable the identification of patients who may be at risk of relapsing at the end of their TB therapy and possibly, more importantly, may have a role in identifying those patients with LTBI that may be at risk of developing active disease. As the tracer [64Cu]Cu-cFLFLF in conjunction with 2-[18F]F-FDG has recently been proven utility in the diagnosis and monitoring of TB in cynomolgus macaques (42), it is the hope that this and future work can be translated adequately into the clinical spectrum which will assist in the resolution of many diagnostic dilemmas and challenges within the TB spectrum and thereby make this tracer a suitable option for routine clinical work.
Figure 3. (A) A TB granuloma with the constellation of different cell types. Macrophages are seen at the centre which can be differentiated into other cell types illustrated. Neutrophils form part of the granuloma. (B) Demonstrates where the 2-[18F]FDG uptake(in faint yellow) is distributed in a granuloma, and not being able to discriminate between the relevant cell types. (C) Shows the projected uptake of FPR1-mediated molecular imaging (in bold yellow) with Gallium-68-nanotracer-cFLFLF highlighting neutrophils in the granuloma.
Author Contributions
SM wrote the manuscript. All authors planned the manuscript content, analysed the literature, wrote parts of it, and edited the final manuscript.
Funding
The authors acknowledge funding from the Wellcome Trust (MM, 206751/Z/17/Z), Bill and Melinda Gates Foundation (MM), and (OPP1210776) SA Medical Research Council (SAMRC) with funding from the SA Department of Health (MM).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
Images created with Biorender.com. The authors would like to thank Gill Morgan for assistance with the initial searches that formed the basis of this article.
References
1. Siemsen JK, Grebe SF, Sargent EN, Wentz D. Gallium-67 scintigraphy of pulmonary diseases as a complement to radiography. Radiology. (1976) 118:371–5. doi: 10.1148/118.2.371
2. Goldfarb CR, Colp C, Ongseng F, Finestone H, Havas J. Gallium scanning in the ‘new’ tuberculosis. Clin Nucl Med. (1997) 22:470–4. doi: 10.1097/00003072-199707000-00005
3. Yeh JJ, Huang YC, Teng WB, Huang YF, Chuang YW, Hsu CC. The role of gallium-67 scintigraphy in comparing inflammatory activity between tuberculous and nontuberculous mycobacterial pulmonary diseases. Nucl Med Commun. (2011) 32:392–401. doi: 10.1097/MNM.0b013e3283449316
4. Abdel-Dayem HM, Naddaf S, Aziz M, Mina B, Turoglu T, Akisik MF, et al. Sites of tuberculous involvement in patients with AIDS. Autopsy findings and evaluation of gallium imaging. Clin Nucl Med. (1997) 22:310–4. doi: 10.1097/00003072-199705000-00007
5. del Val Gómez Martínez M, Gallardo FG, March J, Laguna F. Gallium-67 (Ga-67) scintigraphy in tuberculosis and Mycobacterium avium-M. intracellulare infections in patients with HIV infections. Med Clin (Barc). (1998) 110:570–3.
6. Lee VW, Cooley TP, Fuller JD, Ward RJ, Farber HW. Pulmonary mycobacterial infections in AIDS: characteristic pattern of thallium and gallium scan mismatch. Radiology. (1994) 193:389–92. doi: 10.1148/radiology.193.2.7972748
7. Suga K, Kume N, Orihashi N, Nishigauchi K, Uchisako H, Matsumoto T, et al. Difference in 201Tl accumulation on single photon emission computed tomography in benign and malignant thoracic lesions. Nucl Med Commun. (1993) 14:1071–8. doi: 10.1097/00006231-199312000-00004
8. Yu YH, Hsu WH, Hsu NY, Lin TY, Hsia TC, Sun SS, et al. The use of dual phase 201Tl SPECT for differentiating pulmonary malignancies from benign lesions. Jpn J Clin Oncol. (2004) 34:445–51. doi: 10.1093/jjco/hyh080
9. Kashimada A. Diagnostic abilities of high-resolution CT, dynamic CT, and 201T1 SPECT in evaluating of pulmonary masses. Nihon Igaku Hoshasen Gakkai Zasshi. (1998) 58:407–19.
10. Fujii T, Tanaka M, Koizumi T, Kubo K. Evaluation of Tl-20 lung uptake and impairment of pulmonary perfusion on scintigraphies in pulmonary tuberculosis. Kekkaku. (2000) 75:89–96.
11. Iwata T, Inoue K, Mizuguchi S, Tsukioka T, Morita R, Suehiro S. Thymic tuberculosis preoperatively evaluated with thallium-201 SPECT: two resected cases. Ann Thorac Cardiovasc Surg. (2007) 13:44–6.
12. Giuda DD, Valenza V, Tartaglione T, Squadrito G, Focacci C. False-positive Tl-201 SPECT in a case of cerebral tuberculoma. Clin Nucl Med. (2006) 31:636–7. doi: 10.1097/01.rlu.0000237969.90216.a0
13. Degirmenci B, Kilinc O, Cirak KA, Capa G, Akpinar O, Halilcolar H, et al. Technetium-99m-tetrofosmin scintigraphy in pulmonary tuberculosis. J Nucl Med. (1998) 39:2116–20.
14. Ahmadihosseini H, Sadeghi R, Zakavi R, Kakhki VR, Kakhki AH. Application of technetium-99m-sestamibi in differentiation of active from inactive pulmonary tuberculosis using a single photon emission computed tomography method. Nucl Med Commun. (2008) 29:690–4. doi: 10.1097/MNM.0b013e3283009f22
15. Önsel ç, Sönmezoglu K, çamsari G, Atay S, çetin S, Erdil YT, et al. Technetium-99m-MIBI scintigraphy in pulmonary tuberculosis. J Nucl Med. (1996) 37:233–8.
16. Alavi M, Emad AF, Bahtouee M. 99mTc-hexakis methoxy isobutyl isonitrile MIBI scintigraphy and bronchoalveolar fluid lactic dehydrogenase in pulmonary tuberculosis. Hell J Nucl Med. (2008) 11:110–3.
17. Schuurmans MM, Ellmann A, Bouma H, Diacon AH, Dyckmans K, Bolliger CT. Solitary pulmonary nodule evaluation with 99mTc-methoxy isobutyl isonitrile in a tuberculosis-endemic area. Eur Respir J. (2007) 30:1090–5. doi: 10.1183/09031936.00046107
18. Utsunomiya K, Narabayashi I, Nishigaki H, Tsujimoto K, Kariyone S, Ohnishi S. Clinical significance of thallium-201 and gallium-67 scintigraphy in pulmonary tuberculosis. Eur J Nucl Med. (1997) 24:252–7. doi: 10.1007/BF01728760
19. Lai FM, Liam CK, Paramsothy M, George J. The role of 67gallium scintigraphy and high resolution computed tomography as predictors of disease activity in sputum smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis. (1997) 1:563–9.
20. Lin WY, Wang SJ, Cheng KY, Shen YY, Changlai SP. Diagnostic value of bone and Ga-67 imaging in skeletal tuberculosis. Clin Nucl Med. (1998) 23:743–6. doi: 10.1097/00003072-199811000-00004
21. Lisbona R, Derbekyan V, Novales-Diaz J, Veksler A. Gallium-67 scintigraphy in tuberculous and nontuberculous infectious spondylitis. J Nucl Med. (1993) 34:853–9.
22. Stefanescu C, Rusu V, Boişteanu D, Azoicai D, Costin M, Oleniuc D, et al. 99mTc isonitrils biophysical aspects in pulmonary tuberculosis. Part I in vivo evaluation of 99mTc MIBI and 99mTc Tetrofosmin biophysical localization mechanisms. Rev Med Chir Soc Med Nat Iasi. (2006) 110:944–9.
23. Stefănescu C, Rusu V, Azoicăi D, Hurjui I. 99mTc isonitrils biophysical aspects in pulmonary tuberculosis. Part II in vitro evaluation of 99mTc MIBI cellular uptake mechanism Rev Med Chir Soc Med Nat Iasi. (2007) 111:210–5.
24. Davis SL, Be NA, Lamichhane G, Nimmagadda S, Pomper MG, Bishai WR, et al. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS ONE. (2009) 4e6297-e. doi: 10.1371/journal.pone.0006297
25. Foss CA, Harper JS, Wang H, Pomper MG, Jain SK. Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis. (2013) 208:2067–74. doi: 10.1093/infdis/jit331
26. Ordonez AA, Pokkali S, DeMarco VP, Klunk M, Mease RC, Foss CA, et al. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother. (2015) 59:642–9. doi: 10.1128/AAC.04180-14
27. Malpani BL, Kadival GV, Samuel AM. Radioimmunoscintigraphic approach for the in vivo detection of tuberculomas–a preliminary study in a rabbit model. Int J Rad Appl Instrum B. (1992) 19:45–53. doi: 10.1016/0883-2897(92)90184-Z
28. Lee JD, Shin KH, Cho SN, Shin JS, Lee MG, Yang WI, et al. Immunoscintigraphy in the detection of tuberculosis with radiolabelled antibody fragment against Mycobacterium bovis bacillus Calmette-Guérin: a preliminary study in a rabbit model. Eur J Nucl Med. (1992) 19:1011–5. doi: 10.1007/BF00180861
29. Somawardhana CW, Sajjad M, Amartey JK, Lambrecht RM. Synthesis of 2-[123I and 124I]-iodoisonicotinic acid hydrazide—potential radiotracers for tuberculosis. Int J Radiat Appl Instrument A Appl Radia Isotopes. (1991) 42:215–20. doi: 10.1016/0883-2889(91)90079-G
30. Singh A, Bhatnagar A. Tc-99m-Isoniazid (INH): a specific mycobacterial lesion imaging agent. J Nucl Med. (2008) 49(Suppl. 1):309P-P.
31. Singh AK, Verma J, Bhatnager A, Sen S. Tc-99m isoniazid: a specific agent for diagnosis of tuberculosis. World J Nucl Med. (2003) 2:292–305.
32. Samad A, Sultana Y, Khar RK, Aqil M, Kalam MA, Chuttani K, et al. Radiolabeling and evaluation of alginate blend-isoniazid microspheres by 99mTc for the treatment of tuberculosis in rabbit model. J Drug Target. (2008) 16:509–15. doi: 10.1080/10611860802201076
33. Essouissi I, Saied N, Bernard S, Guizani S, Mejri N, Barc C, et al. 99mTc-N-IFC: a new isoniazid derivative for Mycobacterium diagnostic. Radiochimica Acta. (2012) 100:207–14. doi: 10.1524/ract.2012.1905
34. Essouissi I, Saied NM, Mejri N, Guizani S, Lazim H, Saidi M. Synthesis and biological evaluation of 99mTc-ECF: a new ethionamide derivative for tuberculosis diagnosis. J Radioanal Nucl Chem. (2014) 300:987–96. doi: 10.1007/s10967-014-3059-4
35. Causse JE, Pasqualini R, Cypriani B, Weil R, van der Valk R, Bally P, et al. Labeling of ethambutol with 99mTc using a new reduction procedure. Pharmacokinetic study in the mouse and rat. Int J Radiat Appl Instrument A Appl Radiat Isotopes. (1990) 41:493–6. doi: 10.1016/0883-2889(90)90010-E
36. Singh N, Bhatnagar A. Clinical evaluation of efficacy of (99m)TC -ethambutol in tubercular lesion imaging. Tuberc Res Treat. (2010) 2010:618051. doi: 10.1155/2010/618051
37. Kartamihardja AHS, Kurniawati Y, Gunawan R. Diagnostic value of (99m)Tc-ethambutol scintigraphy in tuberculosis: compared to microbiological and histopathological tests. Ann Nucl Med. (2018) 32:60–8. doi: 10.1007/s12149-017-1220-1
38. Sharma R, Tewari KN, Bhatnagar A, Mondal A, Mishra AK, Singh AK, et al. Tc-99m ciprofloxacin scans for detection of tubercular bone infection. Clin Nucl Med. (2007) 32:367–70. doi: 10.1097/01.rlu.0000259322.31974.e8
39. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. (1992) 33:1972–80.
40. Mattila JT, Beaino W, Maiello P, Coleman MT, White AG, Scanga CA, et al. Positron emission tomography imaging of macaques with tuberculosis identifies temporal changes in granuloma glucose metabolism and integrin α4β1-expressing immune cells. J Immunol. (2017) 199:806–15. doi: 10.4049/jimmunol.1700231
41. Beaino W, Mattila J, Coleman T, Flynn J, Anderson C. PET imaging of immune cells in a macaque tuberculosis model. J Nucl Med. (2015) 56(Suppl. 3):651.
42. Mattila JT, Beaino W, White AG, Nyiranshuti L, Maiello P, Tomko J, et al. Retention of 64Cu-FLFLF, a formyl peptide receptor 1-specific PET Probe, correlates with macrophage and neutrophil abundance in lung granulomas from cynomolgus macaques. ACS Infect Dis. (2021) 7:2264–76. doi: 10.1021/acsinfecdis.0c00826
43. Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med. (2014) 6:265ra167. doi: 10.1126/scitranslmed.3009500
44. Ankrah AO, van der Werf TS, de Vries EF, Dierckx RA, Sathekge MM, Glaudemans AW. PET/CT imaging of Mycobacterium tuberculosis infection. Clin Transl Imaging. (2016) 4:131–44. doi: 10.1007/s40336-016-0164-0
45. Cheng G, Torigian DA, Zhuang H, Alavi A. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging. (2013) 40:779–87. doi: 10.1007/s00259-013-2343-9
46. Sathekge M, Maes A, D'Asseler Y, Vorster M, Gongxeka H, Van de Wiele C. Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging. (2012) 39:1184–90. doi: 10.1007/s00259-012-2115-y
47. Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. (2014) 6:265ra166. doi: 10.1126/scitranslmed.3009501
48. Kim K, Kim SJ, Kim IJ, Kim BS, Pak K, Kim H. Diffuse increased splenic F-18 fluorodeoxyglucose uptake may be an indirect sign of acute pyogenic cause rather than tuberculous in patients with infectious spondylitis. Nucl Med Commun. (2011) 32:1155–61. doi: 10.1097/MNM.0b013e32834bbdf1
49. Kim SJ, Kim IJ, Suh KT, Kim YK, Lee JS. Prediction of residual disease of spine infection using F-18 FDG PET/CT. Spine (Phila Pa 1976). (2009). 34:2424–30. doi: 10.1097/BRS.0b013e3181b1fd33
50. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest. (2003) 124:893–901. doi: 10.1378/chest.124.3.893
51. Vorster M, Stoltz A, Jacobs AG, Sathekge M. Imaging of pulmonary tuberculosis with 18F-fluoro-deoxy-glucose and 18F-ethylcholine. Open Nucl Med J. (2014) 6:17–21. doi: 10.2174/1876388X01406010017
52. Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG. J Nucl Med. (2008) 49:186–94. doi: 10.2967/jnumed.107.044966
53. Tucker EW, Pokkali S, Zhang Z, DeMarco VP, Klunk M, Smith ES, et al. Microglia activation in a pediatric rabbit model of tuberculous meningitis. Dis Model Mech. (2016) 9:1497–506. doi: 10.1242/dmm.027326
54. Zhang Z, Ordonez AA, Smith-Jones P, Wang H, Gogarty KR, Daryaee F, et al. The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography. PLoS ONE. (2017) 12:e0170871. doi: 10.1371/journal.pone.0170871
55. Liu L, Xu Y, Shea C, Fowler JS, Hooker JM, Tonge PJ. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem. (2010) 53:2882–91. doi: 10.1021/jm901858n
56. Weinstein EA, Liu L, Ordonez AA, Wang H, Hooker JM, Tonge PJ, et al. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother. (2012) 56:6284–90. doi: 10.1128/AAC.01644-12
57. Ordonez AA, Weinstein EA, Bambarger LE, Saini V, Chang YS, DeMarco VP, et al. A systematic approach for developing bacteria-specific imaging tracers. J Nucl Med. (2017) 58:144–50. doi: 10.2967/jnumed.116.181792
58. Tucker EW, Guglieri-Lopez B, Ordonez AA, Ritchie B, Klunk MH, Sharma R, et al. Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Sci Transl Med. (2018) 10:eaau0965. doi: 10.1126/scitranslmed.aau0965
59. Ordonez AA, Wang H, Magombedze G, Ruiz-Bedoya CA, Srivastava S, Chen A, et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nat Med. (2020) 26:529–34. doi: 10.1038/s41591-020-0770-2
60. Mota F, Jadhav R, Ruiz-Bedoya C, Ordonez A, Klunk M, Freundlich J, et al. Radiosynthesis and biodistribution of 18 F-Linezolid in Mycobacterium tuberculosis-infected mice using PET. ACS Infect Dis. (2020) 6:916–21. doi: 10.1021/acsinfecdis.9b00473
61. Ordonez AA, Carroll LS, Abhishek S, Mota F, Ruiz-Bedoya CA, Klunk MH, et al. Radiosynthesis and PET bioimaging of (76)Br-bedaquiline in a murine model of tuberculosis. ACS Infect Dis. (2019) 5:1996–2002. doi: 10.1021/acsinfecdis.9b00207
62. Belton M, Brilha S, Manavaki R, Mauri F, Nijran K, Hong YT, et al. Hypoxia and tissue destruction in pulmonary TB. Thorax. (2016) 71:1145–53. doi: 10.1136/thoraxjnl-2015-207402
63. Organisation WH. Global Tuberculosis Report 2020. (2020). Available online at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports (accessed February 1, 2021).
64. The First South African National TB Prevalence Survey gives a clearer picture of the epidemic. www.samrc.ac.za (2021). Available online at: https://www.samrc.ac.za/media-release/first-south-african-national-tb-prevalence-survey-gives-clearer-picture-epidemic (accessed February 22, 2021).
65. Chen DL, Scherer PM, Palestro CJ. Clinical imaging. In: Jain SK, editor. Imaging Infections: From Bench to Bedside. Cham: Springer International Publishing (2017). p. 17–41.
66. Organisation WH. Early Detection of Tuberculosis: An Overview of Approaches, Guidelines and Tools. Geneva: World Health Organization (2011). Available online at: http://who.int/iris/handle/10665/70824#sthash.TN5snAtB.dpuf (accessed March 30, 2021).
67. Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infect Dis. (2014) 14:709. doi: 10.1186/s12879-014-0709-7
68. MacLean E, Kohli M, Weber SF, Suresh A, Schumacher SG, Denkinger CM, et al. Advances in molecular diagnosis of tuberculosis. J Clin Microbiol. (2020) 58:e01582–19. doi: 10.1128/JCM.01582-19
69. Rajamani S, Kuszpit K, Scarff JM, Lundh L, Khan M, Brown J, et al. Bioengineering of bacterial pathogens for noninvasive imaging and in vivo evaluation of therapeutics. Sci Rep. (2018) 8:12618. doi: 10.1038/s41598-018-30806-x
70. Nutma E, Stephenson JA, Gorter RP, de Bruin J, Boucherie DM, Donat CK, et al. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. Brain. (2019) 142:3440–55. doi: 10.1093/brain/awz287
71. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. (2010) 9:971–88. doi: 10.1038/nrd3295
72. Unkart JT, Wallace AM. Use of (99m)Tc-tilmanocept as a single agent for sentinel lymph node identification in breast cancer: a retrospective pilot study. J Nucl Med Technol. (2017) 45:181–4. doi: 10.2967/jnmt.117.194415
73. Lorenzoni A, Santinami M, Maccauro M. Clinical applications of receptor-binding radiopharmaceutical 99mTc-Tilmanocept: sentinel node biopsy and beyond. Clin Transl Imaging. (2020) 8:413–8. doi: 10.1007/s40336-020-00399-5
74. Zanni MV, Toribio M, Wilks MQ, Lu MT, Burdo TH, Walker J, et al. Application of a novel CD206+ macrophage-specific arterial imaging strategy in HIV-infected individuals. J Infect Dis. (2017) 215:1264–9. doi: 10.1093/infdis/jix095
75. Graf J, Abbruzzese B, Cope F, Behr S, Sanders J, Kissling A, et al. AB0248 Evaluation of subcutaneously (SC) injected tc 99m tilmanocept localization in active rheumatoid arthritis (RA) subjects by planar and spect/ct. Ann Rheum Dis. (2018) 77:1305–6. doi: 10.1136/annrheumdis-2018-eular.7533
76. Kardan A, Kissling A, Hartings C, Hershey R, Blue M, Ralph D, et al. A phase I/phase II study of intravenously (IV) administered Tc 99m tilmanocept (TCT) to determine safety, tolerability, optimal clinical dose selection, and imaging timepoint in patients clinically diagnosed with rheumatoid arthritis (RA). J Nucl Med. (2019) 60(Suppl. 1):89.
77. Suzuki Y, Shirai M, Asada K, Yasui H, Karayama M, Hozumi H, et al. Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis. Sci Rep. (2018) 8:13129. doi: 10.1038/s41598-018-31565-5
78. Navidea Announces Comparative Study to Evaluate Tilmanocept in Patients with TB,. (2019). Available online at: https://www.pharmaceutical-business-review.com/news/navidea-announces-comparative-study-to-evaluate-tilmanocept-in-patients-with-tb/ (accessed March 11, 2021).
79. Roohi S, Mushtaq A, Jehangir M, Malik SA. Direct labeling of isoniazid with technetium-99m for diagnosis of tuberculosis. Radiochimica Acta. (2006) 94:147–52. doi: 10.1524/ract.2006.94.3.147
80. Samuel G, Kothari K, Banerjee S, Das T, Subramanian S, Kameshwaran M, et al. On the 99mTc-labeling of isoniazid with different 99mTc cores. J Label Comp Radiopharm. (2005) 48:363–77. doi: 10.1002/jlcr.930
81. Hazari P, Chuttani K, Kumar N, Mathur R, Sharma R, Singh B, et al. Synthesis and biological evaluation of isonicotinic acid hydrazide conjugated with diethyelenetriaminepentaacetic acid for infection imaging. Open Nucl Med J. (2009) 1:33–42. doi: 10.2174/1876388X00901010033
82. Shah SQ, Khan AU, Khan MR. Radiosynthesis and biodistribution of (99m)Tc-rifampicin: a novel radiotracer for in-vivo infection imaging. Appl Radiat Isot. (2010) 68:2255–60. doi: 10.1016/j.apradiso.2010.05.014
83. Diah L, Kartamihardja A. The role of Technetium-99m-Ethambutol scintigraphy in the management of spinal tuberculosis. World J Nucl Med. (2019) 18:13–7. doi: 10.4103/1450-1147.250325
84. Lee M, Yoon M, Hwang KH, Choe W. Tc-99m ciprofloxacin SPECT of pulmonary tuberculosis. Nucl Med Mol Imaging. (2010) 44:116–22. doi: 10.1007/s13139-010-0021-4
85. Bhardwaj V, Agrawal M, Suri T, Sural S, Kashyap R, Dhal A. Evaluation of adequacy of short-course chemotherapy for extraspinal osteoarticular tuberculosis using 99mTc ciprofloxacin scan. Int Orthop. (2011) 35:1869–74. doi: 10.1007/s00264-010-1162-x
86. Palestro CJ. Radionuclide imaging of infection: in search of the grail. J Nucl Med. (2009) 50:671–3. doi: 10.2967/jnumed.108.058297
87. Palestro CJ. Molecular imaging of infection: the first 50 years. Semin Nucl Med. (2020) 50:23–34. doi: 10.1053/j.semnuclmed.2019.10.002
88. Signore A, Jamar F, Israel O, Buscombe J, Martin-Comin J, Lazzeri E. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline. Eur J Nucl Med Mol Imaging. (2018) 45:1816–31. doi: 10.1007/s00259-018-4052-x
89. Sultana S, Buscombe JR, Hilson AJ. In pyrexia resulting from occult tuberculosis Ga-67 citrate is still more sensitive than newer agents such as Tc-99m selusomab. Clin Nucl Med. (2005) 30:414–5. doi: 10.1097/01.rlu.0000162608.57458.c3
90. Kim DG, Lee JI, Lee DS, Lee MC, Choi KS, Han DH. 99mTc-HMPAO labeled leukocyte SPECT in intracranial lesions. Surg Neurol. (1995) 44:338–45. doi: 10.1016/0090-3019(95)00221-9
91. Bester MJ, Van Heerden PD, Klopper JF, Wasserman HJ, Rubow S, de Klerk F. Imaging infection and inflammation in an African environment: comparison of 99Tcm-HMPAO-labelled leukocytes and 67Ga-citrate. Nucl Med Commun. (1995) 16:599–607. doi: 10.1097/00006231-199507000-00012
92. Prat L, Bajén MT, Ricart Y, Roca M, Mora J, Martin-Comin J. Ga-67 citrate and Tc-99m HMPAO leukocyte scanning in extrapulmonary tuberculosis. Clin Nucl Med. (1991) 16:865–6. doi: 10.1097/00003072-199111000-00018
93. Atasever T, Soylu A, Korkmaz M, Aras G, Demirtas M, Erbay G. Mall de Pott. A cause of photopenic lesion on Tc-99m HMPAO-labeled leukocyte scintigraphy. Clin Nucl Med. (1993) 18:88–9. doi: 10.1097/00003072-199301000-00026
94. Sathekge M, Maes A, D'Asseler Y, Vorster M, Van de Wiele C. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals. Nucl Med Commun. (2012) 33:581–90. doi: 10.1097/MNM.0b013e3283528a7c
95. Peppicelli S, Andreucci E, Ruzzolini J, Bianchini F, Calorini L, FDG. uptake in cancer: a continuing debate. Theranostics. (2020) 10:2944–8. doi: 10.7150/thno.40599
96. Basu S, Hess S, Nielsen Braad P-E, Olsen BB, Inglev S, Høilund-Carlsen PF. The basic principles of FDG-PET/CT imaging. PET Clin. (2014) 9:355–70. doi: 10.1016/j.cpet.2014.07.006
97. Heuker M, Sijbesma JWA, Aguilar Suárez R, de Jong JR, Boersma HH, Luurtsema G, et al. In vitro imaging of bacteria using (18)F-fluorodeoxyglucose micro positron emission tomography. Sci Rep. (2017) 7:4973. doi: 10.1038/s41598-017-05403-z
98. Ankrah AO, Glaudemans A, Maes A, Van de Wiele C, Dierckx R, Vorster M, et al. Tuberculosis. Semin Nucl Med. (2018) 48:108–30. doi: 10.1053/j.semnuclmed.2017.10.005
99. Del Giudice G, Bianco A, Cennamo A, Santoro G, Bifulco M, Marzo C, et al. Lung and nodal involvement in nontuberculous mycobacterial disease: PET/CT Role. BioMed Res Int. (2015) 2015:353202. doi: 10.1155/2015/353202
100. Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging. (2009) 36:632–9. doi: 10.1007/s00259-008-1009-5
101. Xu B, Guan Z, Liu C, Wang R, Yin D, Zhang J, et al. Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions? Eur J Nucl Med Mol Imaging. (2011) 38:285–92. doi: 10.1007/s00259-010-1625-8
102. Ordonez AA, DeMarco VP, Klunk MH, Pokkali S, Jain SK. Imaging chronic tuberculous lesions using sodium [(18)F]fluoride positron emission tomography in mice. Mol Imaging Biol. (2015) 17:609–14. doi: 10.1007/s11307-015-0836-6
103. Li Z-B, Wu Z, Cao Q, Dick DW, Tseng JR, Gambhir SS, et al. The synthesis of 18F-FDS and its potential application in molecular imaging. Mol Imaging Biol. (2008) 10:92–8. doi: 10.1007/s11307-007-0125-0
104. Ordonez AA, Wintaco LM, Mota F, Restrepo AF, Ruiz-Bedoya CA, Reyes CF, et al. Imaging Enterobacterales infections in patients using pathogen-specific positron emission tomography. Sci Transl Med. (2021) 13:eabe9805. doi: 10.1126/scitranslmed.abe9805
105. Titgemeyer F, Amon J, Parche S, Mahfoud M, Bail J, Schlicht M, et al. A genomic view of sugar transport in Mycobacterium smegmatis and Mycobacterium tuberculosis. J Bacteriol. (2007) 189:5903–15. doi: 10.1128/JB.00257-07
106. Morgat C, Hindié E, Mishra AK, Allard M, Fernandez P. Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways. Cancer Biother Radiopharm. (2013) 28:85–97. doi: 10.1089/cbr.2012.1244
107. Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev. (2010) 62:1005–22. doi: 10.1016/j.addr.2010.09.004
108. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. RadioGraphics. (2017) 38:200–17. doi: 10.1148/rg.2018170108
109. Vorster M, Maes A. Wiele Cvd, Sathekge M. Gallium-68 PET: a powerful generator-based alternative to infection and inflammation imaging. Semin Nucl Med. (2016) 46:436–47. doi: 10.1053/j.semnuclmed.2016.04.005
110. Ebenhan T, Chadwick N, Sathekge MM, Govender P, Govender T, Kruger HG, et al. Peptide synthesis, characterization and 68Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT. Nucl Med Biol. (2014) 41:390–400. doi: 10.1016/j.nucmedbio.2014.02.001
111. Mokaleng BB, Ebenhan T, Ramesh S, Govender T, Kruger HG, Parboosing R, et al. Synthesis, 68Ga-radiolabeling, and preliminary in vivo assessment of a depsipeptide-derived compound as a potential PET/CT infection imaging agent. Biomed Res Int. (2015) 2015:284354. doi: 10.1155/2015/284354
112. Ebenhan T, Mokaleng BB, Venter JD, Kruger HG, Zeevaart JR, Sathekge M. Preclinical assessment of a (68)Ga-DOTA-functionalized depsipeptide as a radiodiagnostic infection imaging agent. Molecules. (2017) 22:1403. doi: 10.3390/molecules22091403
113. Vorster M, Maes A, Jacobs A, Malefahlo S, Pottel H, Van de Wiele C, et al. Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions. Ann Nucl Med. (2014) 28:523–30. doi: 10.1007/s12149-014-0842-9
114. Kang F, Wang S, Tian F, Zhao M, Zhang M, Wang Z, et al. Comparing the diagnostic potential of 68Ga-Alfatide II and 18F-FDG in differentiating between non small cell lung cancer and tuberculosis. J Nucl Med. (2016) 57:672–7. doi: 10.2967/jnumed.115.167924
115. Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med. (2016) 57:367–71. doi: 10.2967/jnumed.115.164442
116. Ahuja A, Taneja S, Thorat K, Jena A. 68Ga–Prostate-specific membrane antigen–avid tubercular lesions mimicking prostate cancer metastasis on simultaneous prostate-specific membrane antigen PET/MRI. Clin Nucl Med. (2017) 42:e509–e10. doi: 10.1097/RLU.0000000000001874
117. Vorster M, Maes A, van de Wiele C, Sathekge M. 68Ga-citrate PET/CT in tuberculosis: a pilot study. Q J Nucl Med Mol Imaging. (2019) 63:48–55. doi: 10.23736/S1824-4785.16.02680-7
118. Ankrah AO, Lawal IO, Boshomane TMG, Klein HC, Ebenhan T, Dierckx R, et al. Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis. Nuklearmedizin. (2019) 58:371–8. doi: 10.1055/a-1000-6951
119. Gupta N, Elumalai RK, Verma R, Belho ES, Dhawan S. Spinal tuberculosis mimicking as prostate cancer metastases in Ga-68 prostate-specific membrane antigen positron-emission tomography/computed tomography. Indian J Nucl Med. (2020) 35:271–3. doi: 10.4103/ijnm.IJNM_56_20
120. Wong VCK, Shen L, Nasser E, Adams DN, Mansberg R. 68Ga-prostate-specific membrane antigen uptake in cerebral tuberculosis. Clin Nucl Med. (2020) 45:238–40. doi: 10.1097/RLU.0000000000002910
121. Naftalin CM, Leek F, Hallinan JTPD, Khor LK, Totman JJ, Wang J, et al. Comparison of 68Ga-DOTANOC with 18F-FDG using PET/MRI imaging in patients with pulmonary tuberculosis. Sci Rep. (2020) 10:14236. doi: 10.1038/s41598-020-71127-2
122. Gu B, Luo Z, He X, Wang J, Song S. 68Ga-FAPI and 18F-FDG PET/CT images in a patient with extrapulmonary tuberculosis mimicking malignant tumor. Clin Nucl Med. (2020) 45:865–7. doi: 10.1097/RLU.0000000000003279
123. Hao B, Wu X, Pang Y, Sun L, Wu H, Huang W, et al. [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. Eur J Nucl Med Mol Imaging. (2021) 48:651–2. doi: 10.1007/s00259-020-04941-5
124. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun. (2008) 76:2333–40. doi: 10.1128/IAI.01515-07
125. Bresser PL, Vorster M, Sathekge MM. An overview of the developments and potential applications of (68)Ga-labelled PET/CT hypoxia imaging. Ann Nucl Med. (2021) 35:148–58. doi: 10.1007/s12149-020-01563-7
126. Rustad TR, Sherrid AM, Minch KJ, Sherman DR. Hypoxia: a window into Mycobacterium tuberculosis latency. Cell Microbiol. (2009) 11:1151–9. doi: 10.1111/j.1462-5822.2009.01325.x
127. Ferro-Flores G, Avila-Rodríguez MA, García-Pérez FO. Imaging of bacteria with radiolabeled ubiquicidin by SPECT and PET techniques. Clin Transl Imaging. (2016) 4:175–82. doi: 10.1007/s40336-016-0178-7
128. Ujula T, Salomäki S, Virsu P, Lankinen P, Mäkinen TJ, Autio A, et al. Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol. (2009) 36:631–41. doi: 10.1016/j.nucmedbio.2009.04.008
129. Vorster M, Buscombe J, Saad Z, Sathekge M. Past and future of Ga-citrate for infection and inflammation imaging. Curr Pharm Des. (2018) 24:787–94. doi: 10.2174/1381612824666171129200611
130. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative. Intent Eur Urol. (2021) 79:243–62. doi: 10.1016/j.eururo.2020.09.042
131. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. (2021) 79:263–82. doi: 10.1016/j.eururo.2020.09.046
132. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res. (1998) 58:4787–9.
133. Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. (2007) 81:845–55. doi: 10.1189/jlb.0606417
134. Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. (2019) 60:386–92. doi: 10.2967/jnumed.118.215913
135. Dendl K, Koerber SA, Finck R, Mokoala KMG, Staudinger F, Schillings L, et al. (68)Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. (2021). doi: 10.1007/s00259-021-05378-0
136. Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. (2021) 48:4377–85. doi: 10.1007/s00259-021-05307-1
137. Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat Med. (2016) 22:531–8. doi: 10.1038/nm.4073
138. Ndlovu H, Marakalala MJ. Granulomas and inflammation: host-directed therapies for tuberculosis. Front Immunol. (2016) 7:434. doi: 10.3389/fimmu.2016.00434
139. Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol. (2017) 17:691–702. doi: 10.1038/nri.2017.69
140. Marakalala MJ, Martinez FO, Plüddemann A, Gordon S. Macrophage heterogeneity in the immunopathogenesis of tuberculosis. Front Microbiol. (2018) 9:1028. doi: 10.3389/fmicb.2018.01028
141. Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol. (2012) 3:411. doi: 10.3389/fimmu.2012.00411
142. Hilda JN, Das S, Tripathy SP, Hanna LE. Role of neutrophils in tuberculosis: a bird's eye view. Innate Immun. (2020) 26:240–7. doi: 10.1177/1753425919881176
143. Muefong CN, Sutherland JS. Neutrophils in tuberculosis-associated inflammation and lung pathology. Front Immunol. (2020) 11:962. doi: 10.3389/fimmu.2020.00962
144. Lowe DM, Bandara AK, Packe GE, Barker RD, Wilkinson RJ, Griffiths CJ, et al. Neutrophilia independently predicts death in tuberculosis. Eur Respir J. (2013) 42:1752–7. doi: 10.1183/09031936.00140913
145. Lyadova IV. Neutrophils in tuberculosis: heterogeneity shapes the way? Mediators Inflamm. (2017) 2017:8619307. doi: 10.1155/2017/8619307
146. Borchert T, Beitar L, Langer LBN, Polyak A, Wester HJ, Ross TL, et al. Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. J Nucl Cardiol. (2021) 28:1636–45. doi: 10.1007/s12350-019-01929-z
147. Lawal IO, Fourie BP, Mathebula M, Moagi I, Lengana T, Moeketsi N, et al. (18)F-FDG PET/CT as a noninvasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis. J Nucl Med. (2020) 61:412–7. doi: 10.2967/jnumed.119.233783
148. Sathekge MM, Ankrah AO, Lawal I, Vorster M. Monitoring response to therapy. Semin Nucl Med. (2018) 48:166–81. doi: 10.1053/j.semnuclmed.2017.10.004
149. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med. (2016) 22:1094–100. doi: 10.1038/nm.4177
150. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nat Med. (2016) 22:1090–3. doi: 10.1038/nm.4161
151. Malherbe ST, Chen RY, Dupont P, Kant I, Kriel M, Loxton AG, et al. Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response. EJNMMI Res. (2020) 10:8. doi: 10.1186/s13550-020-0591-9
152. Liu Y, Chen K, Wang JM. Chapter 91 - FPR ligands. In: Kastin AJ, editor. Handbook of Biologically Active Peptides. 2d ed. Boston: Academic Press (2013). p. 671–80.
153. Weiß E, Kretschmer D. Formyl-peptide receptors in infection, inflammation, and cancer. Trends Immunol. (2018) 39:815–29. doi: 10.1016/j.it.2018.08.005
154. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. (2002) 23:541–8. doi: 10.1016/S1471-4906(02)02316-5
155. Le Y, Yang Y, Cui Y, Yazawa H, Gong W, Qiu C, et al. Receptors for chemotactic formyl peptides as pharmacological targets. Int Immunopharmacol. (2002) 2:1–13. doi: 10.1016/S1567-5769(01)00150-3
156. Schiffmann E, Corcoran BA, Wahl SM. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci USA. (1975) 72:1059–62. doi: 10.1073/pnas.72.3.1059
157. Anton PA, Targan SR, Shanahan F. Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology. (1989) 97:20–8. doi: 10.1016/0016-5085(89)91410-8
158. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med. (1982) 155:264–75. doi: 10.1084/jem.155.1.264
159. Dorward DA, Lucas CD, Chapman GB, Haslett C, Dhaliwal K, Rossi AG. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. Am J Pathol. (2015) 185:1172–84. doi: 10.1016/j.ajpath.2015.01.020
160. Fischman AJ, Babich JW, Rubin RH. Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Semin Nucl Med. (1994) 24:154–68. doi: 10.1016/S0001-2998(05)80229-6
161. Fischman AJ, Rauh D, Solomon H, Babich JW, Tompkins RG, Kroon D, et al. In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates. J Nucl Med. (1993) 34:2130–4.
162. Babich JW, Tompkins RG, Graham W, Barrow SA, Fischman AJ. Localization of radiolabeled chemotactic peptide at focal sites of Escherichia coli infection in rabbits: evidence for a receptor-specific mechanism. J Nucl Med. (1997) 38:1316–22.
163. Babich JW, Graham W, Barrow SA, Dragotakes SC, Tompkins RG, Rubin RH, et al. Technetium-99m-labeled chemotactic peptides: comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit. J Nucl Med. (1993) 34:2176–81.
164. Fischman AJ, Solomon HF, Babich JW, Abrams MJ, Callahan RJ, Strauss HW, et al. Imaging of focal sites of inflammation in rhesus monkeys with 99mTc-labeled human polyclonal IgG. Nucl Med Biol. (1994) 21:111–6. doi: 10.1016/0969-8051(94)90137-6
165. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. (2009) 24:379–93. doi: 10.1089/cbr.2009.0674
166. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. (2009) 20:825–41. doi: 10.1021/bc800299f
167. Zhang Y, Kundu B, Fairchild KD, Locke L, Berr SS, Linden J, et al. Synthesis of novel neutrophil-specific imaging agents for Positron Emission Tomography (PET) imaging. Bioorg Med Chem Lett. (2007) 17:6876–8. doi: 10.1016/j.bmcl.2007.10.013
168. Locke LW, Chordia MD, Zhang Y, Kundu B, Kennedy D, Landseadel J, et al. A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu. J Nucl Med. (2009) 50:790–7. doi: 10.2967/jnumed.108.056127
169. Pellico J, Lechuga-Vieco AV, Almarza E, Hidalgo A, Mesa-Nuñez C, Fernández-Barahona I, et al. In vivo imaging of lung inflammation with neutrophil-specific (68)Ga nano-radiotracer. Sci Rep. (2017) 7:13242. doi: 10.1038/s41598-017-12829-y
170. Zhang Y, Xiao L, Chordia MD, Locke LW, Williams MB, Berr SS, et al. Neutrophil targeting heterobivalent SPECT imaging probe: cFLFLF-PEG-TKPPR-99mTc. Bioconjug Chem. (2010) 21:1788–93. doi: 10.1021/bc100063a
171. Stasiuk GJ, Long N, Gavins F. Single photon emission computed tomography imaging agents for formyl peptide receptors 1 and 2. FASEB J. (2012) 26:679.3. doi: 10.1096/fasebj.26.1_supplement.679.3
172. Stasiuk GJ, Smith H, Wylezinska-Arridge M, Tremoleda JL, Trigg W, Luthra SK, et al. Gd3+ cFLFLFK conjugate for MRI: a targeted contrast agent for FPR1 in inflammation. Chem Commun (Camb). (2013) 49:564–6. doi: 10.1039/C2CC37460A
173. Stasiuk GJ, Holloway PM, Rivas C, Trigg W, Luthra SK, Morisson Iveson V, et al. 99mTc SPECT imaging agent based on cFLFLFK for the detection of FPR1 in inflammation. Dalton Transactions. (2015) 44:4986–93. doi: 10.1039/C4DT02980A
174. Palestro CJ, FDG-PET. in musculoskeletal infections. Semin Nucl Med. (2013) 43:367–76. doi: 10.1053/j.semnuclmed.2013.04.006
175. Chen J, Cheng H, Dong Q, Chen F, Huang Z, Zhang Y, et al. [99mTc]cFLFLF for early diagnosis and therapeutic evaluation in a rat model of acute osteomyelitis. Mol Imaging Biol. (2015) 17:337–44. doi: 10.1007/s11307-014-0787-3
176. Xiao L, Ding M, Zhang Y, Chordia M, Pan D, Shimer A, et al. A novel modality for functional imaging in acute intervertebral disk herniation via tracking leukocyte infiltration. Mol Imaging Biol. (2017) 19:703–13. doi: 10.1007/s11307-016-1038-6
177. Altun GT, Arslantaş MK, Cinel I. Primary graft dysfunction after lung transplantation. Turk J Anaesthesiol Reanim. (2015) 43:418–23. doi: 10.5152/TJAR.2015.16443
178. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. (2009) 23:2222–32. doi: 10.1038/leu.2009.179
179. Charles EJ, Chordia MD, Zhao Y, Zhang Y, Mehaffey JH, Glover DK, et al. SPECT imaging of lung ischemia-reperfusion injury using [99mTc]cFLFLF for molecular targeting of formyl peptide receptor 1. Am J Physiol Lung Cell Mol Physiol. (2020) 318:L304–13. doi: 10.1152/ajplung.00220.2018
180. Shannon AH, Chordia MD, Spinosa MD, Su G, Ladd Z, Pan D, et al. Single-photon emission computed tomography imaging using formyl peptide receptor 1 ligand can diagnose aortic aneurysms in a mouse model. J Surg Res. (2020) 251:239–47. doi: 10.1016/j.jss.2020.01.028
181. Locke LW, Kothandaraman S, Tweedle M, Chaney S, Wozniak DJ, Schlesinger LS. Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb). (2018) 108:201–10. doi: 10.1016/j.tube.2018.01.001
Keywords: tuberculosis, formyl peptide receptor, Gallium-68, cFLFLF, nuclear medicine, molecular imaging, PET/CT
Citation: More S, Marakalala MJ and Sathekge M (2021) Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers. Front. Med. 8:758636. doi: 10.3389/fmed.2021.758636
Received: 14 August 2021; Accepted: 03 November 2021;
Published: 10 December 2021.
Edited by:
Giorgio Treglia, Ente Ospedaliero Cantonale (EOC), SwitzerlandReviewed by:
Natale Quartuccio, ARNAS Ospedali Civico Di Cristina Benfratelli, ItalyAlberto Miceli, Università di Genova, Italy
Copyright © 2021 More, Marakalala and Sathekge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stuart More, stuart.more@uct.ac.za